WO2026018274 - TRIPLE LAYER TABLET FORMULATION OF TELMISARTAN
National phase entry is expected:
Publication Number
WO/2026/018274
Publication Date
22.01.2026
International Application No.
PCT/IN2025/051059
International Filing Date
16.07.2025
Title **
[English]
TRIPLE LAYER TABLET FORMULATION OF TELMISARTAN
[French]
FORMULATION DE COMPRIMÉ TRICOUCHE DE TELMISARTAN
Applicants **
AKUMS DRUGS & PHARMACEUTICALS LIMITED
Inventors
JAIN, Sanjeev
JAISWAL, Sunil
CHAUDHARY, Arun
CHAUDHARI, Pankaj Hemraj
Priority Data
202411054496
16.07.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2069 | |
| EPO | Filing, Examination, Granting | 12015 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1788 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,628
Contact Us
Abstract[English]
The present invention provides a trilayer tablet formulation containing telmisartan in an immediate release form, along with two additional antihypertensive agents in immediate or extended release forms, addresses the critical challenges of chemical incompatibility and dissolution interference. This advanced formulation strategy holds promise for improving the management of hypertension through more effective and stable combination therapies.[French]
La présente invention concerne une formulation de comprimé tricouche contenant du telmisartan sous une forme à libération immédiate, conjointement avec deux agents antihypertenseurs supplémentaires dans des formes à libération immédiate ou prolongée, relevant les défis critiques de l'incompatibilité chimique et de l'interférence de dissolution. Cette stratégie de formulation avancée améliore la gestion de l'hypertension par l'intermédiaire de polythérapies plus efficaces et stables.